Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-317 in Active Ulcerative Colitis
NCT07834515Phase 1Not yet recruiting
- Sponsor
- Thetis Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Jul 2027
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing Active TP317 80 mg with Placebo (2 arms). Primary endpoints: Safety of TP317 at 12 weeks and Pharmacokinetics of TP317 at 12 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
resolvin e1
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07834515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07834515.